A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma by Dalhoff, K et al.
A phase II study of the vitamin D analogue Seocalcitol in patients
with inoperable hepatocellular carcinoma
K Dalhoff*,1,2, J Dancey
3, L Astrup
4, T Skovsgaard
5, KJ Hamberg
6, FJ Lofts
7, O Rosmorduc
8, S Erlinger
9,
J Bach Hansen
10, WP Steward
11, T Skov
6, F Burcharth
12 and TRJ Evans
13
1Department of Clinical Pharmacology, Rigshospitalet, Denmark;
2Department of Hepatology, Rigshospitalet, Denmark;
3Princess Margaret Division, The
Toronto Hospital, Toronto, Canada;
4Department of Hepatology, Aarhus Kommunehospital, Aarhus, Denmark;
5Department of Oncology, Herlev
Hospital, Herlev, Denmark;
6LEO Pharma A/S, Ballerup, Denmark;
7Department of Medical Oncology, St George’s Hospital, London, UK;
8He `pato-
Gastro-Ente ´rologie, Ho ˆpital Saint-Antoine, Paris, France;
9He `pato-Gastro-Ente ´rologie 2, Ho ˆpital Boujon, Clichy, France;
10Department of Medical
Gastroenterology, Aalborg Hospital, Aalborg, Denmark;
11Medical Oncology, Leicester Royal Infirmary, Leicester, UK;
12Department of Gastrointestinal
Surgery, Herlev Hospital, Herlev, Denmark;
13Department of Medical Oncology, University of Glasgow, UK
Hepatocellular carcinoma (HCC) is a common malignant tumour, which has a poor prognosis. Surgical resection can be curative but
most patients are inoperable and most chemotherapy agents have minimal activity in this disease. Seocalcitol, a vitamin D analogue,
induces differentiation and inhibits growth in cancer cell lines and in vivo. The vitamin D receptor is expressed in hepatocytes and
more abundantly in HCC cells. In total, 56 patients with inoperable advanced HCC were included in an uncontrolled study of oral
Seocalcitol treatment for up to 1 year (with possible extension for responders). The dose was titrated according to serum calcium
levels. The treatment effect was evaluated by regular CT scans. Out of 33 patients evaluable for tumour response, two had complete
response (CR), 12 stable disease and 19 progressive disease. The CRs appeared after 6 and 24 months of treatment, and lasted for
29 and at least 36 months (patient still in remission when data censored). Seocalcitol was well tolerated; the most frequent toxicity
was hypercalcaemia and related symptoms. Most patients tolerated a daily dose of 10mg of Seocalcitol. This is the first study showing
activity, by reduction in tumour dimensions, of a differentiating agent in patients with an advanced bulky, solid tumour. Seocalcitol may
have an effect in the treatment of HCC, especially in early disease when a prolonged treatment can be instituted. The survival benefit
with or without tumour response should be determined in controlled studies.
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Hepatocellular carcinoma (HCC) is one of the most common
malignant tumours in the world accounting for more than 300000
cases per year (Parkin et al, 1993). There is a large geographical
variation, with the annual incidence ranging from less than five
cases per 100000 persons in Europe and North America to around
20 per 100000 in eastern Asia (Parkin et al, 1993). HCC is twice as
common in males as in females, and a strong and consistent
association between HCC and cirrhosis of the liver is found, which
is independent of ethnic group and aetiology of the cirrhosis (HBV
or HCV infection or alcohol) (Zaman et al, 1985). Surgical
resection is considered the most effective treatment, but can rarely
be performed and carries a high operative risk due to the poor
general status of the patients and/or the reduced functional
capacity of the residual cirrhotic liver. Furthermore, the cancer
recurrence rate is approximately 50% at 1 year after potentially
curative resection (Nagasue et al, 1990; Iwatsuki et al, 1991).
Percutaneous ethanol injection, radiofrequency, and transarterial
chemoembolisation are invasive techniques that have shown some
efficacy in reducing tumour bulk, but their ability to improve
survival has yet to be established (Yamada et al, 1990). Similarly,
systemic chemotherapy may induce tumour responses, but
survival benefit has not been clearly demonstrated, and the results
of most chemotherapy agents are disappointing (Falkson et al,
1984; Bruix et al, 2001). In addition, the lack of efficacy of
antiandrogens (Grimaldi et al, 1998) and tamoxifen (Gallo et al,
1998) has also been clearly demonstrated in unresectable HCC.
Consequently, novel approaches are required for the management
of inoperable HCC.
1a,25-dihydroxyvitamin D3 has been shown to exert potent cell
regulatory effects in cells other than those involved in calcium
homeostasis. The effects are thought to be mediated through
binding to an intracellular receptor protein, the vitamin D receptor
(VDR). The receptor–ligand complex interacts with DNA
sequences, leading to activation or suppression of gene transcrip-
tion. More than 50 genes have been shown to be regulated by this
mechanism, among these the cell cycle regulators p21, p27, c-fos
and c-myc. Regulation of these genes may in turn explain the
antiproliferative and differentiating effects of vitamin D and
analogues (for a review see (Hansen et al (2000)), as well as their
ability to inhibit the invasive potential of human cancer cells in
vitro (Hansen et al, 1994) and to inhibit tumour-induced
angiogenesis (Majewski et al, 1993).
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lIn search of a compound with less effect on calcium metabolism
a new vitamin D analogue, Seocalcitol, has been synthesised
(Hansen et al, 2000). Seocalcitol is 50–200 times more potent in
inhibiting proliferation and inducing differentiation of human
cancer cell lines than 1a,25-dihydroxyvitamin D3 (Hansen and
Ma ¨enpa ¨a ¨, 1997). At the same time, Seocalcitol has 50% less
calcaemic effect in rats relative to 1a,25-dihydroxyvitamin D3
(Mathiasen et al, 1993).
In tumour-bearing animals, Seocalcitol has been shown to
suppress growth of chemically induced breast cancer (James et al,
1998) and xenografts of colon cancer (Akhter et al, 1997), breast
cancer (Colston et al, 1992) and pancreatic cancer (Colston et al,
1997a), and to inhibit metastasis from prostate cancer (Lokeshwar
et al, 1999). Vitamin D receptors have been reported to be present
in the liver including human hepatocytes (Berger et al, 1988).
Moreover, the expression of VDRs may be more pronounced in
HCC tissue than in normal or cirrhotic liver tissue (Sakai et al,
1988). A study investigating the antiproliferative effects of 1a,25-
dihydroxyvitamin D3 in seven liver cancer cell lines demonstrated
that VDRs were present in all cell lines (Sakai et al, 1989).
Seocalcitol can also profoundly inhibit the proliferation of the HCC
cell line HEP-G2 compared to untreated controls (Akhter et al,
2001).
Seocalcitol was well tolerated in a phase I clinical study in
patients with breast or colorectal cancer, and on the basis of this
study the recommended daily dose for prolonged treatment was
7mgm
 2day
 1 (Gulliford et al, 1998). Consequently, in view of the
evidence supporting the expression of VDRs in hepatocellular
cancers, and the lack of efficacious systemic therapies in this
disease, a phase II study was performed in patients with inoperable
hepatocellular cancer to determine the objective antitumour
activity of Seocalcitol in this disease.
MATERIALS AND METHODS
Patients
The study was a multicentre, open, noncontrolled trial at centres in
Denmark, France, UK, and Canada. The study was approved by the
Research Ethics Committees or Institutional Review Boards of all
participating institutions, and all patients gave written, informed
consent.
Eligible patients were those with a diagnosis of HCC, verified by
histology or cytology, who were not candidates for liver resection
or liver transplantation, with at least one bidimensionally
measurable lesion, age X18 years, WHO performance status of
0–2, a life expectancy of at least 3 months, an albumin-corrected
serum calcium of o2.65mmoll
 1, and adequate renal (serum
creatinine p2 times the upper limit of normal) and haematological
(Hb X10gdl
 1, WBC X3.0 10
9l
 1, platelets X100 10
9l
 1)
function. Patients with a history of hypercalcaemia, disordered
calcium metabolism, anticancer therapy within the previous 4
weeks, or calcium-lowering therapy within the previous 2 weeks,
were excluded.
Seocalcitol treatment schedules
Seocalcitol was administered once daily prior to the evening meal.
A starting dose of 10mgday
 1 was used in all patients. During an
initial dose-finding phase, the individual patients dosage was
increased every 2 weeks until a dose was reached that resulted in
hypercalcaemia. Hypercalcaemia was initially defined as ionised
serum calcium X1.50mmoll
 1 or albumin-corrected serum
calcium X3.00mmoll
 1; later the limits were lowered to 1.40
and 2.80mmoll
 1, respectively because of clinical experience from
this, and concomitant phase II studies, that marked hypercalcae-
mia was inevitable if the dose was further increased after the first
limits were exceeded.
At ionised serum calcium X1.50mmoll
 1 (albumin-corrected
calcium X3.00mmoll
 1) Seocalcitol was stopped for 1 week and
then recommenced at the dose level immediately below the dose
causing hypercalcaemia, and this was used as the maintenance
dose unless further dose reduction was necessary because of
hypercalcaemia. Dose levels of 5, 10, 15, 20, 30, 40, and 60mg daily
were allowed. Patients could continue treatment for up to 1 year
but were withdrawn earlier if there was evidence of disease
progression or unacceptable toxicity. Treatment could be extended
for patients having response or stable disease (SD) after 1 year.
Before starting Seocalcitol therapy, all patients were seen by a
dietitian and the dietary calcium intake assessed. All patients were
given advice on dietary calcium uptake and encouraged to adhere
to a ‘lowest acceptable calcium diet’ (400mgday
–1 of calcium).
Dietary compliance was checked at follow-up visits by individual
investigators.
Assessment of toxicity and antitumour effect
Prior to starting therapy, all patients underwent clinical assess-
ment and measurement of full blood count, serum urea,
electrolytes, liver function tests, glucose and alfa foeto-protein
(AFP). Serum albumin, creatinine, total calcium and ionised
calcium were also measured and the serum calcium corrected for
albumin using the following formula: albumin-corrected serum
calcium¼total serum calciumþ[(40–serum albumin) 0.02].
Assessment of site, size, and spread of the HCC was performed
by CT scan of the abdomen (and other sites as appropriate) and
chest X-ray up to 2 weeks prior to starting therapy, and marker
lesions with a diameter X10mm were identified.
The serum albumin, calcium (total), creatinine, and ionised
calcium were measured weekly until the serum albumin-corrected
calcium had been stable for 4 weeks at the maximum intended
Seocalcitol dose. Thereafter samples were measured at 4-weekly
intervals. The full blood count and other biochemical analyses,
including AFP, were measured at 4-weekly intervals throughout
the study.
Toxicity was graded by the CTC criteria (Green and Weiss, 1992)
and was recorded at 4-weekly intervals. Similarly, clinical
assessment was performed at 4-weekly intervals throughout the
study. Disease assessments by CT scan were performed after 12, 24,
and 52 weeks of treatment, and response assessments determined
using the SWOG criteria (Green and Weiss, 1992). Tumour
responses were confirmed on a repeat scan performed at least 4
weeks later.
Statistics
The number of patients for inclusion in this study was determined
according to Gehan’s two-stage design for estimating the response
rate (Gehan, 1961). Thus the sample size calculation was based on
the requirement of stopping the study at an early stage if the
response rate is below 20%, and of estimating the response rate
with a standard error less than 0.10. Therefore if there was no
objective response (complete or partial) among the first 14
patients, recruitment of patients would stop. If one or more
responses were observed among these first 14 patients, up to 11
additional patients would be recruited.
Patients who did not complete at least 8 weeks of Seocalcitol at
the maintenance dose were to be replaced. However, 21 patients
were off study before 8 weeks of treatment (Table 3). Most of the
35 patients receiving treatment for at least 8 weeks had one or
more dose reductions because of hypercalcaemia, and only 12
patients received treatment for at least 8 weeks at the individual
maintenance dose. Therefore, it was decided that the formal
Seocalcitol in hepatocellular carcinoma
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lstopping rule of Gehan’s design could not be applied, and the
enrolment was stopped by an ad hoc decision.
The time to disease progression was defined as the time from
start of treatment until progression was first detected or the patient
went off study due to clinical deterioration (without tumour
measurements) or the need for other anticancer treatment. Overall
survival was measured from the start of Seocalcitol treatment until
death from any cause, and analyses performed using the Kaplan–
Meier method.
RESULTS
Patient characteristics
A total of 56 patients were enrolled over a 2-year period from
November 1996 from 12 centres in Denmark, France, UK, and
Canada. Of these, four did not fulfil all in- and exclusion criteria
and two died during the period between the screening visit and the
start of treatment visit. Histological subtype was available for 10
patients, four of whom had fibrolamellar HCC. In total 50 patients
received Seocalcitol treatment and were evaluable for assessment
of safety. In total, 33 patients had repeat disease assessments after
12 weeks therapy and were evaluable for response. The remaining
23 patients died or had clinical disease progression before the first
follow-up CT-assessment, and objective tumour response could
therefore not be assessed (Table 1).
The median age was 62.5 years (range 25–90), 42 (75%) were
male, 14 were female, and 48 (87%) were of WHO performance
status p1, with 41 (73%) of patients having locally advanced
disease only, and 15 (27%) having metastases. In total, 34 patients
had received no other treatment before inclusion in the trial.
Previous treatment (22 patients) included surgical resection (14),
chemotherapy (eight, including alcohol injection in three) and
hormone- or immunotherapy (4), with three patients having
received more than one previous treatment modality.
Efficacy analyses
The best responses of individual patients included two complete
responses (CRs), 12 patients with SD, and 19 with progressive
disease (PD) at 12 weeks (Table 2), for an overall response rate of
3.5%. of the intention-to-treat population. The median time to
progression was 84.5 days, and the median overall survival was 207
days (Table 2, Figure 1). Among the 12 patients with disease
stabilisation as best response, the median time with SD was 101
days.
One of the patients with a CR was a 77-year-old man with
cirrhosis of unknown aetiology. He had three tumours, the largest
of which was 18 18mm. Biopsy showed highly differentiated
HCC. The CR was first documented after 24 weeks of treatment.
After 44 weeks, there was a 10 10mm relapse. The patient
remained on treatment, and a second CR was obtained 22 weeks
later. The patient was withdrawn from the study due to disease
progression after 29 months. Alfa foeto-protein was less than
10ngml
–1 for the first year, then gradually rose to around
330ngml
–1. The Seocalcitol dose was between 10 and 20mgday
 1
during the first 20 weeks, and thereafter maintained at 5mgday
–1.
Vitamin D receptors were present in this patient’s tumour as
determined by Western blot (data not shown).
The other patient who had a CR was a 43-year-old woman who
had no history of cirrhosis, alcohol abuse or hepatitis virus
infection. She had previously undergone a partial hepatectomy for
a highly differentiated HCC. The patient had three recurrent
tumours at inclusion into the study, the largest of which was
35 50mm. Complete response was first observed after 103 weeks
Table 1 Baseline pretreatment characteristics for 56 patients included in
the phase II trial of Seocalcitol for advanced hepatocellular carcinoma
Characteristics No. of patients (%)
Gender
Male 42 (75.0)
Female 14 (25.0)
Extent of disease
Local 41 (73.2)
Metastatic 15 (26.8)
To lung/chest wall 8
To spleen, retroperitoneum, other abdomen 6
To bone and abdomen 1
Previous treatment
a
None 34
Surgery 14
Chemotherapy 8
Hormone/immunotherapy 4
Performance status (WHO)
b
0 26 (47.3)
1 22 (40.0)
2 7 (12.7)
Age (years), median (range) 62.5 (25–90)
AFP (ngml
 1), median (range) 297 (below detection
limit–204,765,000)
aA patient can have more than one treatment.
bMissing observation for one patient.
Table 2 Outcome in 56 patients with advanced hepatocellular
carcinoma included in the phase II trial with Seocalcitol
Best response No. of patients
Complete response 2
Stable disease 12
Progressive disease 19
Not assessed 23
Time to progression median (range) 84.5 (0–833) days
Survival, median (range) 207 (0–1092
a) days
1-year survival 28.6%
2-year survival 5.4%
aThe last patient was censored at 1092 days.
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Figure 1 Survival of 56 patients with advanced hepatocellular carcinoma
included in the trial phase II trial of Seocalcitol.
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lof treatment. Alfa foeto-protein was high initially, decreasing
gradually during treatment, and eventually ended within normal
limits. When last seen, the patient had been on treatment for 36
months and still had a CR. The dose was between 15 and
20mgday
–1 during the first 50 weeks, thereafter 10mgday
–1
(disregarding short treatment pauses because of hypercalcaemia).
Tissue was not available to determine VDR expression in this
patient’s tumour.
Calcium level and Seocalcitol dose
Table 3 gives Seocalcitol treatment duration in all treated
patients. In total, 35 patients (69%) were treated for at least 8
weeks, and 11 for at least 26 weeks. Among the 35 patients
who received treatment for at least 8 weeks, only 12 tolerated
the dose that was determined in the dose-finding phase (the
individual maximum tolerated dose) for at least 8 weeks. The
remaining patients developed hypercalcaemia and had further
dose reductions.
Toxicity
The most frequent toxicity was dose-related hypercalcaemia which
was observed in 80% of the patients (Table 4). Hypercalcaemia
usually resolved after 1 week without treatment. Other toxicities
included nausea (20%), and fatigue (10%). In total, 81 of 96
reported reactions were CTC grades 1-2, 11 were CTC grade 3 (10
hypercalcaemia, one malaise/fatigue/lethargy), and four were CTC
grade 4 (all hypercalcaemia).
DISCUSSION
Seocalcitol is a differentiating agent which has shown promise in
animal models of cancer (Akhter et al, 1997; Colston et al, 1997a;
Lokeshwar et al, 1999). Previous studies with this vitamin D
analogue in breast and colorectal cancer (Gulliford et al, 1998) and
pancreatic cancer (Evans et al, 2002) have not demonstrated any
evidence of antitumour activity as determined by objective
reduction in tumour volume. At the time that this study was
initiated, the primary end point was objective tumour response as
defined by classical criteria based on anatomical changes in
tumour dimensions. Consequently, with a response rate of 3.5%,
the conclusion is that the agent is inactive in this disease using a
response rate of 20% as the definition of activity in Gehan’s design.
However, Seocalcitol induced two CRs in patients with advanced
HCC. Seocalcitol is likely to be cytostatic rather than cytotoxic,
with disease stabilisation the likely clinical manifestation of any
antitumour activity. Consequently the observation of two patients
with CR raises the intriguing notion that Seocalcitol may have
some antitumour activity in advanced HCC. Furthermore, the
responses were durable, lasting for 29 months and at least 36
months. The rarity of spontaneous tumour regression in this
disease, and the durability of the responses observed, support the
notion that Seocalcitol may have activity in this disease.
Previous studies of differentiating agents in malignant disease
have mainly focused on the use of retinoids as cancer chemopre-
vention agents (reviewed in (Evans and Kaye, 1999)), although all-
trans retinoic acid as induction or maintenance treatment can
improve disease-free and overall survival when given in combina-
tion with chemotherapy in APML (Tallman et al, 1997), and
isotretinonin can improve event-free survival following myeloa-
blative chemotherapy and autologous bone marrow transplanta-
tion in children with high-risk neuroblastoma (Matthay et al,
1999). In contrast to these studies of maintenance retinoids in
combination with chemotherapy in minimal residual disease, the
present study is the first human study in which a differentiating
agent has shown activity in reducing tumour volume in solid
tumours when given as a single agent in advanced, bulky disease,
albeit in a small percentage of patients.
This observation requires further investigation within rando-
mised controlled trials comparing Seocalcitol with ‘standard’
therapy, with overall survival as the primary end point, which
may be a more appropriate measure of efficacy for a differentiating
agent, which may inhibit tumour growth rate rather than reduce
tumour size.
It may be speculated that the response rate could be increased
by selecting patients whose tumour expresses the VDR. Informa-
tion on individual patients’ VDR status is, however, difficult to
obtain in a clinical study setting, since reliable immunohisto-
chemical methods for the determination of VDR (on archived,
formalin-fixed biopsies) are not available. Attempts were made in
the present study to obtain snap frozen biopsies from tumours for
the determination of VDR by Western blot where possible,
although this was not an entry criterion for the study. Most
Table 3 Treatment duration in 56 patients with advanced hepatocellular
carcinoma included in the phase II trial with Seocalcitol
Treatment duration with Seocalcitol (weeks) No. of patients (%)
o8 21 (37.5)
8–12 12 (21.4)
13–25 12 (21.4)
26–148 11 (19.6)
Table 4 The most common (44% of patients) adverse drug reactions
Adverse drug reaction Number of patients experiencing
the adverse reaction
Percent of patients experiencing
the adverse reaction
Hypercalcaemia 40 80
Nausea 10 20
Malaise/fatigue/lethargy 5 10
Vomiting 5 10
Anorexia 3 6
Constipation 3 6
Creatinine 3 6
Dizziness/vertigo 3 6
Metabolic, other 3 6
Diarrhoea 2 4
Gastrointestinal, other 2 4
Salivary 2 4
Taste 2 4
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lpatients had already undergone a diagnostic biopsy before study
entry and repeat biopsies could not be justified for study purposes
alone on ethical grounds. Similarly, the lack of frozen tumour
material also meant that determination of VDR mRNA expression
was not possible in this study.
In human liver cancers, one study has found VDR mRNA
expression in all 10 tumours tested (Miyaguchi and Watanabe,
2000), another study found VDR in 10 of 18 tumours tested with a
radioreceptor assay (Sakai et al, 1988). Finally, in vitro studies
indicate that the VDR may be induced by the treatment with
vitamin D and analogues (Mangelsdorf et al, 1987; McDonell et al,
1987; Mahonen et al, 1991; Arbour et al, 1993; Ja ¨a ¨skela ¨inen et al,
2000). Thus, whereas for example antioestrogen treatment relies to
a large extent on the presence of the oestrogen receptor, the effect
of Seocalcitol may not be dependent on the pretreatment presence
of VDR. However, selecting patients in future studies in HCC on
the basis of BCLC or Okuda staging may be more relevant in
identifying patients with small volume, slow-growing disease that
may respond to Seocalcitol, as was the case for the two patients
who had CR in this study. Furthermore, a significant number of
patients in this study had PD and discontinued Seocalcitol before
receiving 8 weeks of therapy. The toxicity profile of Seocalcitol
differs significantly from that of chemotherapy or trans-arterial
chemo-embolisation (TACE). Consequently, future studies could
explore the combination of Seocalcitol with TACE in comparison
with TACE alone in selected patients with unresectable HCC to
determine if Seocalcitol can confer any progression-free survival
advantage when combined with this regional therapeutic ap-
proach, thereby also overcoming the drawback of early disease
progression in patients treated with a putative cytostatic agent
alone.
Dose-dependent hypercalcaemia was the most frequent side
effect. This was expected since the design of the study entailed dose
increments every 2 weeks until hypercalcaemia or near-hypercal-
caemia. The incremental design was chosen because of evidence of
dose-dependent response in in vivo studies (Colston et al, 1992;
Colston et al, 1997b; James et al, 1998). No cases of renal stone
were observed. A maintenance dose of 10mgday
 1 was acceptable
for most patients. Other frequent side effects were mild, and
included nausea and fatigue, which were often interpreted as
secondary to the hypercalcaemia, but may also have been
attributable to the primary disease.
In conclusion, activity of Seocalcitol in HCC was demonstrated,
although this was less than the 20% objective response that is
indicative of activity within the Gehan design. The side effects of
the treatment were minimal and associated with hypercalcaemia.
Randomised controlled trials are necessary to assess the efficacy of
Seocalcitol with regard to survival, and to identify patient
characteristics that may predict benefit from the treatment. The
use of Seocalcitol as an adjuvant therapy after potentially curative
resection (ie in ‘minimal disease states’) in HCC is an intriguing
notion.
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